D. Boral Capital Reiterates Buy Rating for Invivyd (NASDAQ:IVVD)

D. Boral Capital reaffirmed their buy rating on shares of Invivyd (NASDAQ:IVVD) in a research note issued to investors on Monday,Benzinga reports. D. Boral Capital currently has a $9.00 target price on the stock.

A number of other brokerages have also weighed in on IVVD. EF Hutton Acquisition Co. I upgraded shares of Invivyd to a “strong-buy” rating in a research report on Wednesday, October 30th. HC Wainwright reiterated a “buy” rating and issued a $10.00 price target on shares of Invivyd in a research note on Tuesday, February 4th. Finally, Morgan Stanley cut their price objective on Invivyd from $9.50 to $3.55 and set an “overweight” rating for the company in a research report on Wednesday, November 20th. Four analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, Invivyd presently has a consensus rating of “Buy” and a consensus target price of $7.89.

Invivyd Price Performance

IVVD stock opened at $1.23 on Monday. Invivyd has a 1-year low of $0.35 and a 1-year high of $4.74. The business has a 50 day simple moving average of $0.84 and a two-hundred day simple moving average of $0.87. The company has a market capitalization of $147.13 million, a price-to-earnings ratio of -0.63 and a beta of 0.61.

Insider Buying and Selling

In related news, Director Terrance Mcguire sold 160,400 shares of the stock in a transaction dated Wednesday, December 11th. The shares were sold at an average price of $0.59, for a total value of $94,636.00. Following the completion of the transaction, the director now owns 4,202,679 shares of the company’s stock, valued at approximately $2,479,580.61. This trade represents a 3.68 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Over the last 90 days, insiders have sold 816,466 shares of company stock worth $423,214. Insiders own 17.90% of the company’s stock.

Institutional Investors Weigh In On Invivyd

Large investors have recently added to or reduced their stakes in the stock. Proficio Capital Partners LLC bought a new stake in shares of Invivyd in the 3rd quarter valued at approximately $27,000. Jane Street Group LLC raised its holdings in Invivyd by 290.5% during the 4th quarter. Jane Street Group LLC now owns 117,432 shares of the company’s stock valued at $52,000 after buying an additional 87,358 shares during the period. Barclays PLC lifted its position in Invivyd by 7.8% in the fourth quarter. Barclays PLC now owns 127,180 shares of the company’s stock worth $56,000 after buying an additional 9,207 shares during the last quarter. Renaissance Technologies LLC purchased a new position in Invivyd during the fourth quarter worth $74,000. Finally, JPMorgan Chase & Co. increased its position in Invivyd by 644.1% during the fourth quarter. JPMorgan Chase & Co. now owns 256,900 shares of the company’s stock valued at $114,000 after acquiring an additional 222,375 shares during the last quarter. 70.36% of the stock is owned by institutional investors.

About Invivyd

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.